Revolution Medicines, Inc.
27.95xPrice / tangible book
Market cap
$43.63B
Tangible equity (USD)
$1.56B
Price / tangible book
27.95x
Price / book
26.74x
Net income / ending equity
-69.3%
Net income / ending assets
-48.0%
Efficiency ratio
—
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $43.63B · View financials
Snapshot Sep 10, 2026, 12:06 PM ET
Decision snapshot: RVMD stock price vs FCNCA: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at FCNCA's multiple
Needs FCNCA P/B.
Implied fair value · at RVMD's multiple
Needs Book value / share.
Snapshot Sep 10, 2026, 12:07 PM ET
Metric by metric
Filter, sort, and scan the equity metrics that matter most for banks: book value, tangible book, returns, and operating efficiency.
Lower is better
Lower is better
Profitability lag
Asset efficiency lag
Lower is better
Statements
Reported bank earnings and balances, with each company’s reporting period shown.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
Tangible book and profitability anchor a bank, not enterprise value.
Deposits and cash-like balances distort enterprise value for banks, so this section reads equity value, tangible book and profitability instead.
Price / tangible book
Market cap
$43.63B
Tangible equity (USD)
$1.56B
Price / tangible book
27.95x
Price / book
26.74x
Net income / ending equity
-69.3%
Net income / ending assets
-48.0%
Efficiency ratio
—
Price / book
Market cap
—
Tangible equity (USD)
$21.70B
Price / tangible book
—
Price / book
—
Net income / ending equity
9.9%
Net income / ending assets
1.0%
Efficiency ratio
63.5%
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Revolution Medicines, Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
FIRST CITIZENS BANCSHARES INC /DE/ · implied price per share
Bank model off — standard DCF modelling is disabled for financial institutions.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider banking comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
AMGEN INC
RVMD vs AMGN
BRISTOL MYERS SQUIBB CO
RVMD vs BMY
GILEAD SCIENCES, INC.
RVMD vs GILD
INCYTE CORP
RVMD vs INCY
VERTEX PHARMACEUTICALS INC / MA
RVMD vs VRTX
Moderna, Inc.
RVMD vs MRNA
JPMorgan Chase & Co.
RVMD vs JPM
Bank of America Corporation
RVMD vs BAC
Wells Fargo & Company
RVMD vs WFC
Citigroup Inc.
RVMD vs C
PNC Financial Services Group, Inc.
RVMD vs PNC
Truist Financial Corporation
RVMD vs TFC
U.S. Bancorp
RVMD vs USB
Huntington Bancshares Incorporated
RVMD vs HBAN
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.